Badgley Phelps Bell Inc Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Badgley Phelps Bell Inc reduced its stake in Gilead Sciences by 1.52% during the most recent quarter end. The investment management company now holds a total of 204,788 shares of Gilead Sciences which is valued at $17,341,448 after selling 3,171 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on May 2, 2016.Gilead Sciences makes up approximately 1.63% of Badgley Phelps Bell Inc’s portfolio.

Gilead Sciences closed down -1.18 points or -1.37% at $84.68 with 92,71,287 shares getting traded on Friday. Post opening the session at $85.67, the shares hit an intraday low of $84.04 and an intraday high of $85.84 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Btc Capital Management sold out all of its stake in GILD during the most recent quarter. The investment firm sold 2,274 shares of GILD which is valued $192,562.Chicago Partners Investment Group reduced its stake in GILD by selling 423 shares or 14.06% in the most recent quarter. The Hedge Fund company now holds 2,585 shares of GILD which is valued at $228,023. Gilead Sciences makes up approx 0.11% of Chicago Partners Investment Group’s portfolio.Concorde Asset Management boosted its stake in GILD in the latest quarter, The investment management firm added 435 additional shares and now holds a total of 3,655 shares of Gilead Sciences which is valued at $322,408. Gilead Sciences makes up approx 0.37% of Concorde Asset Management’s portfolio.Hills Bank Trust Co boosted its stake in GILD in the latest quarter, The investment management firm added 1,240 additional shares and now holds a total of 7,530 shares of Gilead Sciences which is valued at $664,221. Gilead Sciences makes up approx 0.24% of Hills Bank Trust Co’s portfolio.

On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.